

# Accelerating FemTech: Evaluate

---

## Impact report

# Contents

<b>Programme background</b> .....	<b>1</b>
<b>Programme delivery   All cohorts</b> .....	<b>2</b>
<b>Cohort overview   Accelerating FemTech: Evaluate</b> .....	<b>4</b>
<b>Programme impact   Accelerating FemTech: Evaluate</b> .....	<b>6</b>
<b>Programme outcomes</b> .....	<b>10</b>
Growth: all cohorts.....	10
Investment: all cohorts.....	12
Global: all cohorts.....	14
<b>Opportunities</b> .....	<b>15</b>
Testbed.....	15
Building community.....	15
Economic growth and exports.....	15
<b>Conclusion</b> .....	<b>16</b>
<b>Acknowledgments</b> .....	<b>17</b>

# Accelerating FemTech: Evaluate impact

**10**

later-stage FemTech innovations supported

**100%**

of participants agreed

increased knowledge of relevant healthcare sector

**100%**

of participants agreed

networking and new connections proved valuable, helping commercialisation

**90%**

of participants agreed

increased insight into commercialising new innovations

**100%**

of participants agreed

more aware of important evaluation considerations

**Excellent**

NPS category

# Programme background

Women spend a significantly greater proportion of their lives in ill-health and disability. The awareness of disparities across women's health has grown significantly since the publication of the [Women's Health Strategy for England](#) in 2022. Yet, critical challenges persist, with calls to advance women's health with bold leadership, co-design and co-development, and world-leading research and innovation.

Subsequent national reviews and plans have echoed this, including the [Independent Investigation of the National Health Service in England](#) by Lord Darzi; the [10 Year Health Plan for England](#); and the ongoing [National Maternity and Neonatal Investigation](#) by Baroness Amos. These reports highlight the importance of working with women to address critical healthcare inequalities and disparities in outcomes, as well as improving access, choice and care for women across the country.

In October 2025, the Department of Health and Social Care set out plans to [renew the Women's Health Strategy](#). Initial areas for improvement were also announced, including [adding menopause into routine NHS health checks](#), eliminating [cervical cancer](#) by 2040, and providing free access to [emergency hormonal contraception](#).

High potential innovation, developed by ambitious founders, has the power to accelerate meaningful progress in women's health. Emerging innovators are uniquely positioned to tackle unmet need, while ensuring that new products and services align with the three shifts needed for sustained system-wide impact: analogue to digital; hospital to community; and sickness to prevention. This potential represents a transformative opportunity for women's health, as reflected by **Professor Dame Lesley Regan, Women's Health Ambassador for England**:

"Despite encouraging progress, **too many women here and around the world still feel unheard or dismissed**. They continue to face barriers accessing routine healthcare, leading to poorer health outcomes, and receive inadequate research investment.

That is why, as Women's Health Ambassador, I have been asked to renew the Women's Health Strategy: to assess the progress made since 2022, address enduring gaps and ensure women's health is never neglected again – particularly by building a system that listens to women and tackles persistent inequalities. **Innovation has a vital role to play in closing these gaps**, from earlier diagnosis to more personalised, inclusive models of care.

Programmes such as Accelerating FemTech are therefore essential, helping to unlock **new ideas, support innovators, and translate ambition into practical solutions** that will deliver on our shared priorities for women's health. When we get it right for women, everyone in society benefits."

# Programme delivery

## Accelerating FemTech: all cohorts

Accelerating FemTech, which is funded by the Innovate UK Biomedical Catalyst, recognises the potential of innovation to help address current challenges in women's health and other conditions that affect women differently or disproportionately. It is designed to identify high-potential products and help to drive the commercial and funding momentum needed for long-term success.

The 10 week programme is delivered by the Health Innovation Network South London (HIN) with DigitalHealth.London and national partners. It leads with a collaborative approach to ensure participants directly benefit from expertise, connections and markets from across its national network, providing long-term benefits for women's health across the country.

Two cohorts of the Accelerating FemTech programme were delivered between 2023 and 2025. It supported 33 early-stage innovations, from small to medium-sized enterprises (SMEs) with artificial intelligence (AI)-enabled menopause platforms to university spinouts developing medical devices for in vitro fertilisation (IVF). Of these innovations, 25 companies were awarded feasibility funding through a special closed-call Innovate UK Biomedical Catalyst opportunity, available as part of the Accelerator.

In 2025, the Health Innovation Network South London was recommissioned to deliver Accelerating FemTech: Evaluate, one of five thematic Innovate UK Biomedical Catalyst Accelerators. The series of thematic Accelerators expanded on Innovate UK's longstanding work supporting start-ups, entrepreneurs and spinouts to gain the momentum needed to drive innovation in the healthcare system.

Building on the Accelerating FemTech programme for early-stage companies and recognising the demand for tailored support from innovators at more advanced stages of development, Accelerating FemTech: Evaluate was designed for later-stage innovations for women's health with a technology readiness level (TRL) 4 or above. The programme aimed to bridge the gap between visionary women's health solutions and the complex realities of healthcare markets, enabling growth through tailored support, planning strategic partnerships and refining pathways for real-world evaluation, such as health economic analyses.

Ten companies were selected after a robust four week application phase, which included a national roadshow with events in London, Liverpool and Glasgow. Demand for the programme was high, with more than six applications submitted for every place available. Across the three years, the programme has seen a total of 271 applications, helping to address unmet need in women's health by establishing a pipeline of 43 high-potential products.

Accelerating FemTech: Evaluate was delivered between November 2025 and February 2026, with the cohort benefitting from a hybrid curriculum of support, delivered in collaboration with a national network of partners. Eight regional health innovation networks helped to provide one-to-one business coaching, mentoring and expert-led workshops, on topics including value propositions; medical device regulatory pathways; and evidence generation for clinical effectiveness and cost benefit. In-person residential events, networking dinners with clinicians and investors, and a final Showcase complemented this virtual curriculum, providing opportunities for the cohort to connect and exchange knowledge with national stakeholders in different areas of women's health.



3



# Cohort Overview


## Accelerating FemTech: Evaluate

The Accelerating FemTech: Evaluate programme supported 10 innovations for women's health, with technology types ranging from non-digital medical devices for miscarriage care; wearables for breast tenderness; topical solutions to protect intimate health; AI-powered tools for detection of respiratory diseases and early-stage breast cancer; digital therapeutics for navigating Premenstrual Dysphoric Disorder (PMDD) and menopause; Virtual Reality (VR)-enabled platforms for maternity workforce training; and apps for chronic pelvic pain support and navigating motherhood.









Products were designed for a range of market types, demonstrating the breadth of opportunity to engage with women and offer choice. These include NHS services across primary care, secondary care and community care; private healthcare and healthcare insurance; and direct to consumers through app stores and retail; and corporate sector employers.

4

### Area of innovation



## Cohort innovations

	<b>Belle Health</b>	Digital therapeutic for Premenstrual Dysphoric Disorder (PMDD), which is clinically validated and CE-certified (MDR Class I).
	<b>Bloume Health</b>	Personalised pain companion app for chronic pelvic pain linked to endometriosis and other gynaecological conditions.
	<b>Breath Predict</b>	Exhale-Dx™ is an AI powered breath analysis for early, non-invasive detection of respiratory diseases, such as asthma and Chronic Obstructive Pulmonary Disease (COPD).
	<b>Dignity Care Network</b>	The Miscarriage Collection Cradle and Miscarriage Care Kits provide compassionate, dignified and practical support for women experiencing miscarriage in both home and clinical settings.
	<b>Lumino</b>	Seren is a digital therapeutic that delivers digital, Cognitive Behavioural Therapy (CBT)-led menopause support.
	<b>Matresa</b>	Digital preventative maternal health platform, providing personalised support for women from fertility through to return to work and beyond.
	<b>Meyva</b>	The Meyva Heated Bra is designed to help women manage breast tenderness related to the menstrual cycle, breastfeeding and general hormonal fluctuations.
	<b>Niramai Health Analytix</b>	Thermalytix is a novel, AI-powered breast health screening test that works for women of all ages and breast densities.
	<b>P.Happi</b>	The P.Happi Intimate Microbiome Serum contains a naturally occurring unique predatory bacterium, Bdellovibrio bacteriovorus (B.Y.M.® 1405), to support microbiome imbalances that can make women more prone to urinary tract infections (UTIs), thrush, Bacterial vaginosis (BV) and vaginal dryness.
	<b>Upskill.Health</b>	A mobile-based, bitesize training platform that re-imagines how NHS maternity staff are upskilled, embedding learning “in the flow” of clinical work through a combination of mobile, AI and VR technologies.

# Programme impact

## Accelerating FemTech: Evaluate

Accelerating FemTech: Evaluate has delivered a highly impactful and beneficial programme, evidenced through the Net Promotor Score (NPS) in the “Excellent” category. This expands on the success of the previous two early-stage cohorts of Accelerating FemTech, demonstrating the value of building on an existing programme to offer support to companies at a different level of maturity. The programme design responded directly to feedback from previous participants, as well as actively exploring areas for growth identified in the [Accelerating FemTech 2023-2025 evaluation](#).

The 12 week Accelerating FemTech: Evaluate programme delivered around 94 hours of bespoke support to each of the 10 companies, enabling them to refine their evaluation pathways and benefit from brokered introductions to potential investors, clinical partners and evaluation partners. 100% of participants said they would take learnings back to share in their companies, with the Information Governance webinar receiving the highest satisfaction score (4.86 out of 5).

Furthermore, 100% of participants agreed that the programme increased their knowledge of their relevant healthcare sector. Eight out of ten companies developed an evaluation partnership as a result of the programme, with organisation types including:

- Charities
- Community pharmacies
- Health Innovation Networks - Evaluation teams
- NHS England
- NHS Trusts (Secondary Care)
- Primary Care Networks
- Research groups
- Universities

"I've really enjoyed the programme, the showcase (compared to three years ago) has improved significantly and has allowed me to have two potential clinical partnerships."

**P.Happi**

"The connections and the understanding practically of partnership with the NHS [was key for me]. I know I needed to understand what these steps look like and make the right connections in order to support this. It has opened so, so many doors for me, so thank you very much."

**Matresa**

"The hybrid curriculum leveraged an existing network of supporters, whilst establishing new connections who were highly motivated to be involved in the programme. This was enhanced by engagement from organisations across the UK, including Business Coaches and subject matter experts from the regional health innovation networks, and advisors, speakers and supporters from the NHS and industry organisations.

Most notably, this included the Minister for Digital Innovation and Safety, the Regional Director for NHS England London and the Executive leadership of Royal College of Obstetricians and Gynaecologists... I cannot overstate how incredible this has been, and the support has been critical to help my business grow."

**Dignity Care Network**

7



Since the conclusion of the programme, the cohort of companies are preparing to apply for a special closed-call funding opportunity through the Innovate UK Biomedical Catalyst (BMC), which is offered through the programme. 100% of companies agreed that the programme helped with their preparation for this competition. This funding will drive the evaluation activities identified through the programme, which include health economic analysis and technical file development for medical device certification. Companies are also focusing on their growth through raising private investment, navigating new healthcare market segments and exploring international expansion.



**100%**

of participants agreed

**discussions with experts have provided insights that will help to develop the business**



**100%**

of participants agreed

**the opportunity to network and make new connections was highly valuable**



**90%**

of participants agreed

**the programme increased insight and awareness into commercialising new innovations**


## Accelerating FemTech: Evaluate case studies

Click the company spotlight graphics below to read the case studies in full.

**Dignity Care Network:** improving access to safe, dignified and compassionate miscarriage care



**Matresa:** making maternal healthcare personal



**Niramai Health Analytix:** supporting accessible, early breast cancer detection with AI and thermal imaging



**P.Happi:** Smart microbiome serum developed for women seeking a non-antibiotic approach to support bladder



# Programme outcomes

## Growth: all cohorts

Across three years of the Accelerating FemTech programme, 43 companies have been helped to accelerate the growth of their innovations. Whilst they have typically been at an early stage of product or commercial development, there have been some specific growth areas.

**Funding for product and founder development:** 25 companies received Innovate UK Biomedical Catalyst funding in 2024 and 2025 for their technical feasibility studies, with others going on to win NIHR, SBRI and Innovate UK grants to develop the products and support leadership of businesses.

**New products to market:** business to consumer (B2C) products and services have been launched by companies through app stores and direct online sign-ups. Products include **Taahirah (cohort 2)**, an innovative digital health solution designed to support the reproductive health needs of Muslim women; and **28X (cohort 2)**, a subscription-free menstrual app that provides clinical, personalised health content.

**Contracts:** companies have started to secure commercial partnerships with the NHS including a London Integrated Care Board procurement, the retail sector and an international company that designs, manufactures and supplies advanced medical imaging systems. Companies from all three cohorts of the programme also help to drive the growing awareness of women's health and the role of innovation.

**Showcase opportunities:** founders continue to actively participate in and showcase their innovations at conferences in the UK and globally, including:

- Baltic Endovascular Course 2026 Conference (Bulgaria)
- ChangeNOW 2025 - Microsoft Entrepreneurship for Positive Impact (Paris)
- Digital Health Rewired 2025 and 2026
- GIANT Health Event 2024 & 2025
- Hello Tomorrow 2025 (Paris)
- HETT Show 2025
- ICT & Health Global Conference 2026
- International Continence Society 2025 (Abu Dhabi)
- Royal college of Midwives Conference 2025
- Slush 2024 - Health and MedTech Showcase (Finland)
- UK Continence Society 2024
- Women's Health: Empowering the future conference 2025

**Awards and media:** companies have also been recognised across the globe, winning awards and being featured by major media outlets, including:

- **Aiatella (cohort 2)** won the Iceland Innovation Week 'Fermented Shark Tank' Competition in 2025.
- **Birthglide (cohort 1)** won the Early Stage Innovation Award 2023 at VentureFest South.
- **Daye (cohort 2)** won the 2026 Digital Health Rewired Pitchfest competition.
- **Dignity Care Network and Matresa (cohort 3)** have featured on BBC Radio Nottingham and GB News respectively.
- **Megi Health (cohort 2)** went on to be part of the DigitalHealth.London Accelerator and participated in the UK's Pitch in Parliament: AI in Healthcare session in February 2026.
- **Papcup (cohort 2)** won the Emerging Pioneer Award at Hello Tomorrow (2025) in Paris and has been featured on BBC News.
- **Upskill.Health (cohort 2 and 3)** were finalists for two consecutive years of the Digital Health Rewired Pitchfest, being highly commended in 2025.



**Image 1 - Awards ceremony at the Accelerating FemTech: Evaluate Showcase.** From left to right: Rishi Das-Gupta, Chief Executive, Health Innovation Network South London; Laura Corcoran, Founder and CEO, Dignity Care Network; Geetha Manjunath, Founder and CEO, Niramai Health Analytix; Chiara Board, Founder and CEO, P.Happi; Kate Lancaster, CEO, Royal College of Obstetricians and Gynaecologists; and Sara Nelson, Programme Director, Health Innovation Network South London.

## Investment: all cohorts

The current scale of opportunity in women's health is rapidly growing. For years, the FemTech sector has been underestimated and subsequently underinvested in. With FemTech innovations addressing the needs of half the population, the implications for productivity, wellbeing and economic resilience are significant. Investing in women's health generates significant returns, which are both measurable and meaningful.

A [recent NHS Confederation report](#) estimated that for every additional £1 of public investment in obstetrics and gynaecology services per woman in England, there is an estimated return on investment (ROI) of £11. Furthermore, a [report from McKinsey and the World Economic Forum](#) suggested that closing the women's health gap on a global scale could yield 75 million disability-adjusted life years annually. This is the equivalent of adding seven healthy days per year per woman, with the potential to [unlock \\$1 trillion in annual global Gross Domestic Product \(GDP\) by 2040](#). These aren't marginal gains; they're shifts that create value across health systems and economies, as well as making a real impact for women, with the opportunity to live healthier and longer.

Early-stage innovation is where the boldest ideas live, but it's also where the funding gap is the greatest. A central pillar of the Accelerating FemTech programme has been connecting women's health investors with innovators. Strengthening these relationships and brokering opportunities through our investment dinners and one-to-one follow up drives growth across businesses and the sector. Investment groups that supported Accelerating FemTech: Evaluate, for example, include 24Haymarket; Apposite Capital; Better Society Capital; Black Opal Ventures; Calculus Capital; Eka Ventures; InHealth Ventures; Lavender Ventures; Maven Capital Partners; RYSE; and YNM Ventures.

In the last few years, we have seen a significant rise in interest in FemTech investment, with the [FemTech sector having raised over £400m](#). This includes many of the alumni of the Accelerating FemTech programme, who have gone on to not only secure the non-dilutive Innovate UK Biomedical Catalyst Funding, but also private investment to fund development and testing of products. Some examples include:

- **28X:** [£1.2 million funding from the Philips Foundation and 40 mission-driven philanthropic angel investors \(March 2026\)](#)
- **Emm Health:** [£6.8 million in an oversubscribed funding round from Lunar Ventures \(December 2025\)](#)
- **IVFmicro:** [£3.5M in pre-seed funding from Northern Gritstone \(December 2025\)](#)
- **Joi:** [€2.4 million raised with EIT Digital's Equity Profolio, NIHR, Innovate UK and angel investment \(June 2025\)](#)
- **Level Zero Health:** [\\$6.9M pre-seed round led by redalpine \(February 2026\)](#)
- **Matresa:** [£315,000 in pre-seed funding, led by SFC Capital \(February 2026\)](#)
- **MyBliss:** [£100,000 raised with Mint Ventures and co-investment from Alma Angels and Lifted Ventures \(December 2025\)](#)
- **Plexā:** [\\$4.5M raised to launch in US with TCP Health Ventures and THENA Capital \(July 2025\)](#)



**Image 2 - Pitching Q&A at the Accelerating FemTech: Evaluate Showcase.** From left to right: Mari-Carmen Sanchez-Morris, Founder and CEO, Matresa; Joanna Hayman, Associate Medical Director, Circle Health; Issra Siddique, Strategic Partnership Consultant; Asma Khalil, Professor of Maternal Foetal Medicine, St. George's Hospital and Director of Foetal Medicine Unit, Liverpool Women's Hospital; and Anurag Hegde, Head of Healthcare Service Partnerships, Boots UK.

## Global: all cohorts

The UK has the potential to become a “FemTech superpower,” with UK-born innovation for women’s health accounting for [over \\$1.5 billion \(2.68%\) of the global market in 2024](#). This is expected to grow by [around 16.8% by 2030](#), which will be bolstered further by a [commitment from the UK government of £6.1 billion in funding for research and innovation](#).

The Health Innovation Network South London connects innovators to initiatives that are propelling FemTech on a global scale, as well as leveraging international networks to amplify UK-born innovation and share knowledge across borders.

Following their participation in the Accelerating FemTech programmes, six innovations have been selected to participate in the [Innovate UK Global Business Innovation Programme](#), which showcases UK-founded innovations at various health care forums and institutions in countries such as Japan, Germany and the US.

On the back of this, alumni company Plexaa were selected to be part of the Texas Medical Centre Innovation Factory Global Incubator Programme. Since 2025, Plexaa has been implemented in healthcare institutions in California and New York. In November 2024, Plexaa won the ‘FemTech Product of the Year’ at the MedTech World Awards in Malta. Now, the company’s Bloom<sup>43</sup> app is available in more than 150 territories worldwide.

Through the Accelerating FemTech programme, participants have also been introduced to partners working to advance women’s health on a global scale, including Royal College of Obstetrics and Gynaecology, the Canadian High Commission and global health strategist. The cohorts have also included globally established companies looking to navigating the UK market, including Niramai Health Analytix, Megi Health and Aiatella. This creates a community of learning and knowledge exchange, supporting both the imports and exports of high-potential innovation for women’s health.

# Opportunities



## Testbed

Delivering a thematic accelerator that addresses the strategic priorities for women's health, whilst providing bespoke support for innovators in this field means that innovations are being developed to directly address unmet need across women's health. By focusing on the specific gaps and overlooked challenges within women's health, there is a testbed to find, test and implement innovations grounded in real-world need. This targeted approach not only accelerates the progress of high-potential ideas but also ensures that emerging innovations are better positioned to improve outcomes, support equity and contribute to long-term systemic change in women's health.



## Building community

Convening women's health leaders from across the NHS, academia, charities and industry with FemTech innovators and people with lived experience is key to transforming momentum into sustained action. Maintaining engagement and growing this community is key to ensuring the gender health gap is tackled by raising awareness, inspiring bold leadership and unlocking new markets. A national lens also ensures that the advancement of women's health is not a postcode lottery, with geographies embedding co-design and co-development, sharing expertise and learnings, and spreading evaluated innovation across the country. By working together, we can cement the position of the UK as a leader in women's health on the global stage.

15



## Economic growth and exports

Research, development and innovation within women's health have historically been underinvested, but the tide is beginning to turn. The pipeline of high-potential innovation for women's health is already experiencing growth with public and private capital. FemTech is a rapidly growing market, and this momentum will continue to drive innovation at scale, generating revenue and jobs, supporting international exports, and enabling women to remain active in the workforce.

# Conclusion

Three years of delivering the Innovate UK Biomedical Catalyst-funded Accelerating FemTech programme has created opportunities to drive innovation market readiness, establish collaborations and broker evaluation partnerships. These outcomes are helping to create an environment that drives forward women's health innovation, enhancing clinical outcomes, improving quality of life for women and delivering economic growth.

This is evidenced by what our alumni are going on to achieve and the impact they are already having in women's health across the UK and globally. Accelerated by the knowledge, network and collaborations formed through the programme, these companies are reaching new milestones, including raising over an estimated £25 million in investment and establishing partnerships across the NHS, research, charities and academia. Despite their early maturity levels, this pipeline of 43 innovations is set to make a real impact in women's health, backed by the programme's national network.

Looking forward, it will be crucial to view women's health innovation through a lens of three opportunities: maintaining a **testbed** to find, test and implement high potential innovations addressing unmet need; **building community** to bring together bold leadership, lived experience and knowledge across the country; and transforming momentum into sustained action by keeping UK-born FemTech at the forefront of **economic growth and exports**. By seizing these opportunities, the UK can firmly cement itself as a global leader in women's health, driving meaningful progress towards closing the gender health gap.

The Accelerating FemTech: Evaluate programme is testament to what can be achieved when we come together, share knowledge, raise awareness and make connections. Together, we are making a real impact in women's health.

# Acknowledgments

The Accelerating FemTech programme thrived thanks to sustained commitment and collaboration with our national network. For Accelerating FemTech: Evaluate, we extend our sincere thanks to our commissioner, Innovate UK; partners; advisory panel; business coaches; mentors; subject matter experts; supporters of the programme; and the 43 innovative companies that are driving high-potential FemTech innovation. Together, we are making a real impact in women's health.

## Commissioner

- Innovate UK
  - Chris Sawyer
  - Hannah Thomas
  - Samana Brannigan

## Partners

- CW+
- Digital Health & Care Innovation Centre
- Health Innovation Research Alliance Northern Ireland
- Mills & Reeve
- Royal College of Obstetricians and Gynaecologists
- Health Innovation Network
- Health Innovation East
- Health Innovation East Midlands
- Health Innovation North East and North Cumbria
- Health Innovation North West Coast
- Health Innovation Oxford and Thames Valley
- Health Innovation Wessex
- Health Innovation West of England
- Health Innovation Yorkshire and Humber

## Advisory panel

- Dr. Aamena Salar
- Prof. Asma Khalil
- Dr. Edward Morris CBE
- Gail Armstrong
- Kate Lancaster
- Katherine Church
- Lucy Brett
- Dr. Natalie Nunes
- Nicola Bruce
- Prof. Wendy Tindale OBE

## Business coaches

- Aimee Ward
- Gemma Snell
- Iain Taylor
- Moesha Lamptey
- Vanessa Ponnusamy

## Mentors

- Alex Leach
- Prof. Gary Ford CBE
- Joanna Dempsey
- Julian Patel
- Matthew Lawrence
- Mike Kenny
- Philip Shelton
- Mark Edgington
- Sean Clarkson
- Tim Robinson

## Subject matter experts

- Alison Mlot
- Charlotte Lewis
- Dr. Edward Morris CBE
- Glen Howard
- Jonathan Rowley
- Guy Checketts
- Dr. Mamta Bajre
- Paul Merison
- Rebekah Lloyd
- Sarah Cowlshaw
- Sarah Robinson
- Salim Badat
- Zickie Lim

## Individuals and organisations who supported recruitment, programme delivery and shared expertise at events

- Health Innovation Policy Team, Office of Life Science, UK
- Kings College London
- Kings Health Partners
- Royal Society of Medicine
- Women's Health Policy Team, Department of Health & Social Care
- Aahuti Rai
- Aitian Li
- Alexandra Brown
- Alexandra Lindsay
- Alison Wright
- Amanda Begley
- Dr. Amanda Penny
- Amir Golbang
- Prof. Andrew George MBE
- Andrew Walker
- Ann O'Neill
- Anna King
- Anne Oyewole
- Anurag Hegde

- Dr. Beth Jones
- Carey McClellan
- Carina Tyrell
- Caroline Clarke
- David Porter
- David Seemungal
- Estia Ryan
- Professor Dame Lesley Regan
- Gabi Cohen
- Gail Armstrong
- Dr. Gareth Obery
- Gemma Jones
- George Batchelor
- George London
- Hayley Hand
- Prof. Henry Potts
- Dr. Israa Siddig
- Prof. Jane Sandall CBE
- Jennifer Owen
- Joanna Hayman
- Judith Murray
- Dr. Kate Dodd
- Kerry Buckley
- Kreena Dhiman
- Lavanya Bhamidipati
- Dr. Lesley Kay
- Manish Miglani
- Dr. Natasha Curran
- Dr. Nina Breujnung-Joshi
- Nina Capital
- Nina Janda
- Dr. Rishi Das-Gupta
- Samana Brannigan
- Dr. Sarah Bolton
- Sophie Lowry
- Prof. Stamtina Iliodromiti
- Prof. Stella Vig
- Dr. Sunita Sharma
- Vivien de Tusch-Lec
- Minister Zubir Ahmed

